Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry

Muniesa Montserrat, CristinaGallardo, F. (Fernando)García-Doval, IgnacioEstrach Panella, Ma. Teresa (María Teresa)Combalia, AndreaMorillo, MercedesDe la Cruz-Vicente, FátimaMachan, SalmaMoya-Martínez, CristinaRovira, RogerSanchez-Gonzalez, BlancaAcebo, ElviraAmutio, ElenaPeñate, YeraiLosada-Castillo, Maria del CarmenGarcia-Muret, Maria P.Iznardo, HelenaRomán-Curto, ConcepciónCañueto, JavierFernández-de-Misa, RicardoFlórez, ÁngelesIzu, RosaTorres-Navarro, IgnacioZayas, AnaPérez-Paredes, GemaBlanes, MarYanguas, J. IgnacioPérez-Ferriols, AmparoCallejas-Charavia, MartaOrtiz-Romero, Pablo LuisPérez Gil, AmaliaPrieto-Torres, LuciaGonzález Barca, EvaServitje Bedate, Octavio2022-10-212023-08-052022-08-050926-9959https://hdl.handle.net/2445/190046Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.14 p.application/pdfeng(c) European Academy of Dermatology and Venereology, 2022LimfomesCèl·lules TQuimioteràpiaLymphomasT cellsChemotherapyBrentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registryinfo:eu-repo/semantics/article7259572022-10-21info:eu-repo/semantics/openAccess